Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
deaths (OS) | 0.90 [0.78, 1.04] | | < 1 | | 0% | 2 studies (2/-) | 92.8 % | some concern | not evaluable | moderate | crucial | - |
progression or deaths (PFS) | 0.87 [0.65, 1.18] | | < 1 | | 42% | 2 studies (2/-) | 81.3 % | some concern | not evaluable | moderate | important | - |
objective responses (ORR) | 1.36 [0.50, 3.70] | | > 1 | | 77% | 2 studies (2/-) | 72.8 % | some concern | not evaluable | moderate | non important | - |
safety endpoints 00 |
AE (any grade) | 0.53 [0.30, 0.91] | | < 1 | | 0% | 2 studies (2/-) | 98.9 % | some concern | not evaluable | moderate | non important | - |
AE (grade 3-4) | 0.88 [0.61, 1.27] | | < 1 | | 44% | 2 studies (2/-) | 74.6 % | some concern | not evaluable | moderate | non important | - |
AE leading to death (grade 5) | 1.93 [1.14, 3.29] | | < 1 | | 0% | 2 studies (2/-) | 0.8 % | some concern | not evaluable | moderate | non important | - |
AE leading to treatment discontinuation (any grade) | 1.33 [0.95, 1.84] | | < 1 | | 0% | 2 studies (2/-) | 4.7 % | some concern | not evaluable | moderate | non important | - |
AE leading to treatment discontinuation (grade 3-4) | 2.14 [1.32, 3.47] | | < 1 | | 0% | 1 study (1/-) | 0.1 % | NA | not evaluable | | non important | - |
SAE (any grade) | 1.86 [1.31, 2.62] | | < 1 | | 0% | 2 studies (2/-) | 0.0 % | some concern | not evaluable | moderate | non important | - |
STRAE (any grade) | 1.52 [1.03, 2.24] | | < 1 | | 0% | 1 study (1/-) | 1.7 % | NA | not evaluable | | non important | - |
STRAE (grade 3-4) | 1.43 [0.92, 2.21] | | < 1 | | 0% | 1 study (1/-) | 5.6 % | NA | not evaluable | | non important | - |
TRAE (any grade) | 0.33 [0.25, 0.44] | | < 1 | | 0% | 2 studies (2/-) | 100.0 % | some concern | not evaluable | moderate | non important | - |
TRAE (grade 3-4) | 0.53 [0.40, 0.71] | | < 1 | | 0% | 2 studies (2/-) | 100.0 % | some concern | not evaluable | moderate | non important | - |
TRAE leading to death (grade 5) | 1.69 [0.45, 6.29] | | < 1 | | 0% | 2 studies (2/-) | 21.7 % | some concern | not evaluable | moderate | non important | - |
TRAE leading to discontinuation (any grade) | 1.55 [1.03, 2.32] | | < 1 | | 0% | 2 studies (2/-) | 1.7 % | some concern | not evaluable | moderate | non important | - |
TRAE leading to discontinuation (grade 3-4) | 2.95 [1.51, 5.78] | | < 1 | | 0% | 1 study (1/-) | 0.1 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) endpoints 00 |
Acute kidney injury TRAE (grade 3-4) | 1.27 [0.04, 38.28] | | < 1 | | 0% | 1 study (1/-) | 44.5 % | NA | not evaluable | | non important | - |
Adrenal insufficiency TRAE (grade 3-4) | 2.97 [0.31, 28.17] | | < 1 | | 0% | 2 studies (2/-) | 17.3 % | some concern | not evaluable | moderate | non important | - |
Alopecia TRAE (grade 3-4) | 0.95 [0.02, 47.95] | | < 1 | | 0% | 1 study (1/-) | 51.0 % | NA | not evaluable | | non important | - |
Anaemia TRAE (grade 3-4) | 0.06 [0.00, 0.91] | | < 1 | | 59% | 2 studies (2/-) | 97.7 % | some concern | not evaluable | moderate | non important | - |
Asthenia TRAE (grade 3-4) | 0.24 [0.01, 4.80] | | < 1 | | 46% | 2 studies (2/-) | 82.4 % | some concern | not evaluable | moderate | non important | - |
Colitis TRAE (grade 3-4) | 7.43 [0.93, 59.26] | | < 1 | | 0% | 2 studies (2/-) | 3.0 % | some concern | not evaluable | moderate | non important | - |
Constipation TRAE (grade 3-4) | 0.47 [0.02, 14.16] | | < 1 | | 0% | 1 study (1/-) | 66.4 % | NA | not evaluable | | non important | - |
Decreased appetite TRAE (grade 3-4) | 0.83 [0.27, 2.59] | | < 1 | | 0% | 2 studies (2/-) | 62.7 % | some concern | not evaluable | moderate | non important | - |
Diabetes TRAE (grade 3-4) | 1.90 [0.06, 56.82] | | < 1 | | 0% | 1 study (1/-) | 35.8 % | NA | not evaluable | | non important | - |
Diarrhoea TRAE (grade 3-4) | 3.94 [1.13, 13.81] | | < 1 | | 0% | 2 studies (2/-) | 1.6 % | some concern | not evaluable | moderate | non important | - |
Dyspnoea TRAE (grade 3-4) | 2.56 [0.11, 57.33] | | < 1 | | 0% | 1 study (1/-) | 27.9 % | NA | not evaluable | | non important | - |
Fatigue TRAE (grade 3-4) | 0.83 [0.36, 1.95] | | < 1 | | 0% | 2 studies (2/-) | 66.2 % | some concern | not evaluable | moderate | non important | - |
Hepatitis TRAE (grade 3-4) | 4.15 [0.64, 26.90] | | < 1 | | 8% | 2 studies (2/-) | 6.8 % | some concern | not evaluable | moderate | non important | - |
Hypersensitivity TRAE (grade 3-4) | 1.27 [0.04, 38.28] | | < 1 | | 0% | 1 study (1/-) | 44.5 % | NA | not evaluable | | non important | - |
Hypertension TRAE (grade 3-4) | 1.27 [0.11, 14.23] | | < 1 | | 0% | 1 study (1/-) | 42.2 % | NA | not evaluable | | non important | - |
Hyperthyroidism TRAE (grade 3-4) | 1.19 [0.09, 15.52] | | < 1 | | 0% | 2 studies (2/-) | 44.8 % | some concern | not evaluable | moderate | non important | - |
Hypophysitis TRAE (grade 3-4) | 1.56 [0.14, 17.23] | | < 1 | | 0% | 2 studies (2/-) | 36.0 % | some concern | not evaluable | moderate | non important | - |
Hypothyroidism TRAE (grade 3-4) | 2.55 [0.24, 27.62] | | < 1 | | 0% | 2 studies (2/-) | 22.2 % | some concern | not evaluable | moderate | non important | - |
Increase AST TRAE (grade 3-4) | 0.63 [0.01, 32.23] | | < 1 | | 0% | 1 study (1/-) | 58.8 % | NA | not evaluable | | non important | - |
Increased ALT TRAE (grade 3-4) | 0.63 [0.04, 10.24] | | < 1 | | 0% | 1 study (1/-) | 62.5 % | NA | not evaluable | | non important | - |
Increased lipase level TRAE (grade 3-4) | 0.63 [0.01, 32.23] | | < 1 | | 0% | 1 study (1/-) | 58.8 % | NA | not evaluable | | non important | - |
Infusion-related reactions TRAE (grade 3-4) | 0.63 [0.01, 32.23] | | < 1 | | 0% | 1 study (1/-) | 58.8 % | NA | not evaluable | | non important | - |
Leucopenia TRAE (grade 3-4) | 0.10 [0.01, 2.08] | | < 1 | | 0% | 1 study (1/-) | 92.8 % | NA | not evaluable | | non important | - |
Myositis TRAE (grade 3-4) | 0.63 [0.01, 32.23] | | < 1 | | 0% | 1 study (1/-) | 58.8 % | NA | not evaluable | | non important | - |
Nausea TRAE (grade 3-4) | 0.21 [0.03, 1.38] | | < 1 | | 0% | 2 studies (2/-) | 94.6 % | some concern | not evaluable | moderate | non important | - |
Nephritis TRAE (grade 3-4) | 0.95 [0.02, 47.95] | | < 1 | | 0% | 1 study (1/-) | 51.0 % | NA | not evaluable | | non important | - |
Neutropenia TRAE (grade 3-4) | 0.02 [0.00, 0.13] | | < 1 | | 0% | 2 studies (2/-) | 100.0 % | some concern | not evaluable | moderate | non important | - |
Pancreatitis TRAE (grade 3-4) | 2.56 [0.11, 57.33] | | < 1 | | 0% | 1 study (1/-) | 27.9 % | NA | not evaluable | | non important | - |
Peripheral oedema TRAE (grade 3-4) | 1.27 [0.04, 38.28] | | < 1 | | 0% | 1 study (1/-) | 44.5 % | NA | not evaluable | | non important | - |
Pneumonia TRAE (grade 3-4) | 0.63 [0.01, 32.23] | | < 1 | | 0% | 1 study (1/-) | 58.8 % | NA | not evaluable | | non important | - |
Pneumonitis TRAE (grade 3-4) | 7.30 [1.34, 39.79] | | < 1 | | 0% | 2 studies (2/-) | 1.1 % | some concern | not evaluable | moderate | non important | - |
Pruritic rash TRAE (grade 3-4) | 1.27 [0.04, 38.28] | | < 1 | | 0% | 1 study (1/-) | 44.5 % | NA | not evaluable | | non important | - |
Pruritus TRAE (grade 3-4) | 0.78 [0.05, 12.45] | | < 1 | | 0% | 2 studies (2/-) | 57.0 % | some concern | not evaluable | moderate | non important | - |
Pyrexia TRAE (grade 3-4) | 0.32 [0.01, 9.50] | | < 1 | | 0% | 1 study (1/-) | 74.3 % | NA | not evaluable | | non important | - |
Rash TRAE (grade 3-4) | 0.51 [0.08, 3.12] | | < 1 | | 0% | 2 studies (2/-) | 76.8 % | some concern | not evaluable | moderate | non important | - |
Stomatitis TRAE (grade 3-4) | 1.27 [0.04, 38.28] | | < 1 | | 0% | 1 study (1/-) | 44.5 % | NA | not evaluable | | non important | - |
Thrombocytopenia TRAE (grade 3-4) | 0.06 [0.01, 0.46] | | < 1 | | 0% | 2 studies (2/-) | 99.6 % | some concern | not evaluable | moderate | non important | - |
Thyroiditis TRAE (grade 3-4) | 0.63 [0.01, 32.23] | | < 1 | | 0% | 1 study (1/-) | 58.8 % | NA | not evaluable | | non important | - |
Vomiting TRAE (grade 3-4) | 0.13 [0.01, 1.14] | | < 1 | | 0% | 2 studies (2/-) | 96.6 % | some concern | not evaluable | moderate | non important | - |
Weight decreased TRAE (grade 3-4) | 1.27 [0.04, 38.28] | | < 1 | | 0% | 1 study (1/-) | 44.5 % | NA | not evaluable | | non important | - |
AE (grade 3-4) endpoints 00 |
Alopecia AE (grade 3-4) | 0.95 [0.02, 47.95] | | < 1 | | 0% | 1 study (1/-) | 51.0 % | NA | not evaluable | | non important | - |
Anaemia AE (grade 3-4) | 0.12 [0.05, 0.28] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
Asthenia AE (grade 3-4) | 0.86 [0.36, 2.05] | | < 1 | | 0% | 1 study (1/-) | 63.4 % | NA | not evaluable | | non important | - |
Back pain AE (grade 3-4) | 0.63 [0.10, 3.80] | | < 1 | | 0% | 1 study (1/-) | 69.2 % | NA | not evaluable | | non important | - |
Constipation AE (grade 3-4) | 1.90 [0.17, 21.07] | | < 1 | | 0% | 1 study (1/-) | 30.1 % | NA | not evaluable | | non important | - |
Cough AE (grade 3-4) | 0.95 [0.02, 47.95] | | < 1 | | 0% | 1 study (1/-) | 51.0 % | NA | not evaluable | | non important | - |
Decreased appetite AE (grade 3-4) | 1.43 [0.40, 5.11] | | < 1 | | 0% | 1 study (1/-) | 29.1 % | NA | not evaluable | | non important | - |
Diarrhoea AE (grade 3-4) | 2.12 [0.73, 6.17] | | < 1 | | 0% | 1 study (1/-) | 8.4 % | NA | not evaluable | | non important | - |
Dyspnoea AE (grade 3-4) | 1.11 [0.37, 3.33] | | < 1 | | 0% | 1 study (1/-) | 42.7 % | NA | not evaluable | | non important | - |
Fatigue AE (grade 3-4) | 1.31 [0.52, 3.31] | | < 1 | | 0% | 1 study (1/-) | 28.1 % | NA | not evaluable | | non important | - |
Nausea AE (grade 3-4) | 0.63 [0.18, 2.25] | | < 1 | | 0% | 1 study (1/-) | 76.2 % | NA | not evaluable | | non important | - |
Neutropenia AE (grade 3-4) | 0.01 [0.00, 0.19] | | < 1 | | 0% | 1 study (1/-) | 99.9 % | NA | not evaluable | | non important | - |
Pruritus AE (grade 3-4) | 0.95 [0.02, 47.95] | | < 1 | | 0% | 1 study (1/-) | 51.0 % | NA | not evaluable | | non important | - |
Pyrexia AE (grade 3-4) | 0.95 [0.02, 47.95] | | < 1 | | 0% | 1 study (1/-) | 51.0 % | NA | not evaluable | | non important | - |
Rash AE (grade 3-4) | 0.95 [0.06, 15.23] | | < 1 | | 0% | 1 study (1/-) | 51.5 % | NA | not evaluable | | non important | - |
Thrombocytopenia AE (grade 3-4) | 0.03 [0.00, 0.42] | | < 1 | | 0% | 1 study (1/-) | 99.4 % | NA | not evaluable | | non important | - |
Vomiting AE (grade 3-4) | 0.13 [0.02, 1.09] | | < 1 | | 0% | 1 study (1/-) | 96.9 % | NA | not evaluable | | non important | - |
Weight decreased AE (grade 3-4) | 2.86 [0.30, 27.64] | | < 1 | | 0% | 1 study (1/-) | 18.3 % | NA | not evaluable | | non important | - |